GSK plc (LSE:GSK) — Market Cap & Net Worth
Market Cap & Net Worth: GSK plc (GSK)
GSK plc (LSE:GSK) has a market capitalization of $853.19 Million (GBX7.01 Trillion) as of October 11, 2026. Listed on the LSE stock exchange, this UK-based company holds position #9604 globally and #34 in its home market, demonstrating a -2.51% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GSK plc's stock price GBX1750.00 by its total outstanding shares 4007030598 (4.01 Billion).
GSK plc Market Cap History: 2015 to 2026
GSK plc's market capitalization history from 2015 to 2026. Data shows growth from $438.71 Million to $853.19 Million (6.58% CAGR). Check GSK plc share price for real-time trading data and today's change.
Index Memberships
GSK plc is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE All-Share
FTAS
|
$64.95 Billion | 1.31% | #13 of 573 |
|
FTSE 350
FTLC
|
$64.85 Billion | 1.32% | #14 of 350 |
|
FTSE 100 Index (UK)
FTSE
|
$55.11 Billion | 1.55% | #10 of 100 |
|
STOXX Europe Large 200 EUR Price
LCXP
|
$7.18 Trillion | 0.01% | #123 of 182 |
|
STOXX Europe Large 200 Net Return
LCXR
|
$7.18 Trillion | 0.01% | #123 of 182 |
|
FTSE 350 Pharmaceuticals & Biotechnology
NMX4570
|
$3.20 Billion | 26.68% | #2 of 6 |
Weight: GSK plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
GSK plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GSK plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see GSK plc cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.03x
GSK plc's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.16x
GSK plc's market cap is 0.16 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $524.57 Million | $27.89 Billion | $912.00 Million | 0.02x | 0.58x |
| 2017 | $467.82 Million | $30.19 Billion | $1.53 Billion | 0.02x | 0.31x |
| 2018 | $556.81 Million | $30.82 Billion | $3.62 Billion | 0.02x | 0.15x |
| 2019 | $697.77 Million | $33.75 Billion | $4.64 Billion | 0.02x | 0.15x |
| 2020 | $552.89 Million | $34.10 Billion | $5.75 Billion | 0.02x | 0.10x |
| 2021 | $700.31 Million | $24.70 Billion | $4.38 Billion | 0.03x | 0.16x |
| 2022 | $648.33 Million | $29.32 Billion | $14.96 Billion | 0.02x | 0.04x |
| 2023 | $680.33 Million | $30.33 Billion | $4.93 Billion | 0.02x | 0.14x |
| 2024 | $656.47 Million | $31.38 Billion | $2.58 Billion | 0.02x | 0.25x |
| 2025 | $889.52 Million | $32.67 Billion | $5.72 Billion | 0.03x | 0.16x |
Competitor Companies of GSK by Market Capitalization
Companies near GSK plc in the global market cap rankings as of October 11, 2026. See net asset quality index of GSK plc to understand what proportion of total assets are financed by equity.
Key companies related to GSK plc by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #14 globally with a market cap of $1.05 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #21 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #46 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #14 | Eli Lilly and Company | NYSE:LLY | $1.05 Trillion | $1179.27 |
| #21 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $261.44 |
| #46 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $276.47 |
GSK plc Historical Marketcap From 2015 to 2026
Between 2015 and today, GSK plc's market cap moved from $438.71 Million to $ 853.19 Million, with a yearly change of 6.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX853.19 Million | -4.08% |
| 2025 | GBX889.52 Million | +35.50% |
| 2024 | GBX656.47 Million | -3.51% |
| 2023 | GBX680.33 Million | +4.94% |
| 2022 | GBX648.33 Million | -7.42% |
| 2021 | GBX700.31 Million | +26.66% |
| 2020 | GBX552.89 Million | -20.76% |
| 2019 | GBX697.77 Million | +25.32% |
| 2018 | GBX556.81 Million | +19.02% |
| 2017 | GBX467.82 Million | -10.82% |
| 2016 | GBX524.57 Million | +19.57% |
| 2015 | GBX438.71 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 11th, 2026 the market cap of GSK plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $853.19 Million USD |
| MoneyControl | $853.19 Million USD |
| MarketWatch | $853.19 Million USD |
| marketcap.company | $853.19 Million USD |
| Reuters | $853.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more